← Leaderboards
Shengqiang Li
Medimmune Vaccines, Inc.
$8,290,368
Attributed
$8,290,368
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $999.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,290,368 · 6
By mechanism
R44$4,729,473 · 2
UC1$2,680,016 · 1
R43$854,879 · 2
RC1$26,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentReceptorViral Load ResultAntibodiesAnimal ModelCollaborationsRecombinant VaccinesSmall Business Innovation Research GrantVaccine EfficacyVirusVaccinesBindingEvaluationImmunizeManufacturing ProcessEscherichia ColiEnzyme-Linked Immunosorbent AssayBiologicalBetaretrovirusEngineeringGtp-Binding ProteinsCotton RatsAnimalsCytoplasmic Tail
Grant awards (11)
Novel G protein-based RSV vaccine$972,321
R44 · FY2025 · AI · contact PI
Novel G protein-based RSV vaccine$996,326
R44 · FY2024 · AI · contact PI
Novel G protein-based RSV vaccine$999,290
R44 · FY2023 · AI · contact PI
Optimization of G Protein-based RSV Vaccines$298,738
R43 · FY2021 · AI · contact PI
Optimization of G Protein-based RSV Vaccines$299,501
R43 · FY2020 · AI · contact PI
Development of a novel quadrivalent seasonal influenza vaccine using E.coli production technology$301,767
R44 · FY2018 · AI · contact PI
Development of a novel quadrivalent seasonal influenza vaccine using E.coli production technology$722,269
R44 · FY2017 · AI · contact PI
Development of a novel quadrivalent seasonal influenza vaccine using E.coli production technology$737,500
R44 · FY2016 · AI · contact PI
Improved Genetically Modified H5N1 Influenza Vaccine$256,640
R43 · FY2005 · AI
Live attenuated vaccines for pandemic preparedness$2,680,016
UC1 · FY2000 · AI
LIVE ATTENUATED VACCINES FOR PANDEMIC PREPAREDNESS$26,000
RC1 · FY2000 · AI